SGLT2 Inhibitors and Healthy Aging: What Do the Strongest Clinical Trials Show?

1. SGLT2 inhibitors substantially reduced kidney disease progression

Compared with placebo, SGLT2 inhibitors reduced the relative risk of kidney disease progression by 37%.

Relative risk: 0.63 (95% CI 0.58–0.69).

Kidney disease progression was defined using clinically important outcomes, including a sustained major decline in kidney function, progression to very low kidney function or end-stage kidney disease, and death from kidney failure.

The proportional benefit was broadly consistent in people with and without diabetes.

This provides strong randomized evidence that the kidney benefits of SGLT2 inhibitors are not confined to people with diabetes.

2. Acute kidney injury was also less common

SGLT2 inhibitors reduced the relative risk of acute kidney injury by 23%.

Relative risk: 0.77 (95% CI 0.70–0.84).

This is clinically important because acute kidney injury can accelerate loss of kidney function and can have particularly serious consequences in older or medically vulnerable people.

3. Heart failure and cardiovascular outcomes improved

SGLT2 inhibitors reduced the combined risk of cardiovascular death or hospitalization for heart failure by 23%.

Relative risk: 0.77 (95% CI 0.74–0.81).

Cardiovascular death alone was reduced by approximately 14%.

Relative risk: 0.86 (95% CI 0.81–0.92).

These findings support the role of SGLT2 inhibitors as cardiovascular and kidney protective therapies, extending beyond their original use as glucose-lowering drugs.

However, non-cardiovascular mortality was not significantly reduced.

Relative risk: 0.94 (95% CI 0.88–1.02).

This is important when considering the findings from a longevity perspective. The study demonstrated major cardiorenal benefits, but it did not establish a general reduction in all causes of death.

4. Benefits were also present in people without diabetes

One of the most important findings was that the proportional cardiovascular and kidney benefits were generally consistent in participants with and without diabetes.

This indicates that the clinical benefits of SGLT2 inhibition extend beyond glucose lowering alone.

But this finding needs to be interpreted carefully.

The participants without diabetes were generally people with heart failure or chronic kidney disease. They were not a population of healthy adults taking SGLT2 inhibitors for prevention or longevity.

The study therefore supports the use of SGLT2 inhibitors in appropriately selected patients without diabetes. It does not demonstrate that healthy people without diabetes would benefit from taking these drugs.

5. Benefits must be considered alongside safety

The analysis also assessed serious safety outcomes, including ketoacidosis and lower-limb amputation.

These adverse events are important when considering SGLT2 inhibitor therapy. However, in the populations studied, the estimated absolute cardiovascular and kidney benefits outweighed these serious hazards.

As with any preventive or long-term treatment, the balance between benefit and risk depends on the patient’s underlying clinical risk.

6. The study did not test whether SGLT2 inhibitors slow aging

The trials evaluated major cardiovascular and kidney outcomes.

They did not test biological aging, epigenetic age, cellular senescence or other direct measures of the aging process.

They also did not study SGLT2 inhibitors as longevity treatments in healthy people.

The results therefore provide strong evidence for cardiovascular and kidney protection, but they do not demonstrate that SGLT2 inhibitors directly slow biological aging.

Healthy aging depends not only on the biological processes occurring inside cells, but also on preventing or delaying diseases that progressively reduce health, function and independence.

The evidence for SGLT2 inhibitors is particularly important because their cardiovascular and kidney benefits have been demonstrated in large randomized trials.

These benefits also extend to selected patients without diabetes, showing that the clinical effects of SGLT2 inhibition cannot be explained simply by improved glucose control.

However, “without diabetes” should not be interpreted as “healthy.”

The trials do not establish that people without cardiovascular or kidney disease should take SGLT2 inhibitors to prevent aging. They also do not establish that these drugs slow biological aging or extend lifespan in healthy humans.

What the evidence does support is more specific: cardiovascular and kidney protection provides a clinically plausible pathway through which SGLT2 inhibitors may indirectly support healthspan in appropriately selected patients.

Whether SGLT2 inhibitors also influence the underlying biology of aging is a separate question that requires different evidence.

This analysis provides strong clinical evidence because it combines data from large randomized, placebo-controlled trials and evaluates major health outcomes rather than relying only on laboratory biomarkers.

It also changes how SGLT2 inhibitors should be understood.

Their clinical value is no longer confined to glucose control in type 2 diabetes. In appropriately selected patients with heart failure or chronic kidney disease, important cardiovascular and kidney benefits can occur even in the absence of diabetes.

This has potential relevance to healthy aging.

Heart failure and progressive kidney disease can reduce physical capacity, independence and survival. By reducing heart failure hospitalizations and slowing kidney disease progression, SGLT2 inhibitors may indirectly help preserve health and function in appropriately selected high-risk patients.

This represents a potential indirect contribution to healthspan through disease prevention and organ protection, rather than evidence of a direct effect on biological aging.